Comparative Pharmacology
Head-to-head clinical analysis: BETHKIS versus KANTREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETHKIS versus KANTREX.
BETHKIS vs KANTREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tobramycin, an aminoglycoside antibiotic, binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis and causing mRNA misreading.
4 IU/kg (1 mg/kg) intramuscularly or subcutaneously once weekly for 4 weeks, then a maintenance dose of 2 IU/kg (0.5 mg/kg) once weekly.
15 mg/kg/day IM or IV divided every 8-12 hours (not to exceed 1.5 g/day)
None Documented
None Documented
Terminal elimination half-life 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min).
2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; clinically significant accumulation in renal impairment requires monitoring
Primarily renal excretion of unchanged drug via glomerular filtration; ~90% of absorbed dose excreted in urine within 24 hours; biliary/fecal elimination <5%.
Renal: 80-100% as unchanged drug via glomerular filtration; fecal: <1%
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic